Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers

Not Applicable

Completed

• Conditions: Chronic Lower Leg Ulcer
• Interventions: Other: Metalloproteinase Inhibitor; Other: Autologous Platelet Enriched Gel

• Registration Number: NCT00658983
• Lead Sponsor: University Hospital, Ghent

Brief Summary

Compare Autologous Platelet Enriched Gel versus Metalloproteinase Inhibitor in the healing of chronic lower leg ulcers.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-04-01
• Study First Submitted: 2008-04-07
• Study First Submitted QC: 2008-04-14
• Study First Posted: 2008-04-16
• Primary Completion: 2010-08-20
• Study Completion: 2010-08-20
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-03
• Last Update Posted: 2023-01-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

• 18 year or older
• A non-healing chronic lower leg ulcer
• Platelet ranges of 150000 per ml circulating blood

Exclusion Criteria

• Presence of a tumor or metastatic disease
• Hypersensitive to collagen regenerated cellulose
• Hemodynamic unstable patient
• Hypercoagulability
• Heart decompensation or angina pectoris

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Metalloproteinase Inhibitor	Metalloproteinase Inhibitor (Promogran)
1	Autologous Platelet Enriched Gel	Autologous Platelet Enriched Gel

Primary Outcome Measures

Name	Time	Method
Wound healing	6 weeks

Secondary Outcome Measures

Name	Time	Method
Wound healing	6 months

Trial Locations

Locations (1)

University Hospital Ghent; 🇧🇪 Ghent, Belgium